Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Geode Capital Management LLC increased its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,432,697 shares of the company's stock after buying an additional 136,458 shares during the quarter. Geode Capital Management LLC owned 1.42% of Day One Biopharmaceuticals worth $19,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after acquiring an additional 1,002 shares during the last quarter. Quest Partners LLC boosted its stake in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after purchasing an additional 7,668 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $124,000. Hsbc Holdings PLC acquired a new position in Day One Biopharmaceuticals during the 2nd quarter valued at approximately $163,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Day One Biopharmaceuticals in the third quarter worth $174,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $35.71.

Day One Biopharmaceuticals Trading Down 0.2 %

DAWN traded down $0.03 during midday trading on Friday, hitting $12.87. 702,904 shares of the company were exchanged, compared to its average volume of 959,783. The company's 50 day simple moving average is $13.86 and its 200 day simple moving average is $14.02. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -12.50 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.94 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter in the previous year, the company earned ($0.54) EPS. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the sale, the insider now directly owns 1,057,535 shares in the company, valued at $17,026,313.50. This trade represents a 0.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 51,745 shares of company stock valued at $748,567 in the last 90 days. 8.40% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.